The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved..
Glioblastoma (GBM) contains a population of stem-like cells that promote tumor invasion and resistance to therapy. Identifying and targeting stem cell factors in GBM may lead to the development of more effective therapies. High Mobility Group AT-hook 2 (HMGA2) is a transcriptional modulator that mediates motility and self-renewal in normal and cancer stem cells. We identified increased expression of HMGA2 in the majority of primary human GBM tumors and cell lines compared to normal brain. Additionally, HMGA2 expression was increased in CD133+ GBM neurosphere cells compared to CD133- cells. Targeting HMGA2 with lentiviral short hairpin RNA (shRNA) led to decreased GBM stemness, invasion, and tumorigenicity. Ectopic expression of HMGA2 in GBM cell lines promoted stemness, invasion, and tumorigenicity. Our data suggests that targeting HMGA2 in GBM may be therapeutically beneficial.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:377 |
|---|---|
| Enthalten in: |
Cancer letters - 377(2016), 1 vom: 10. Juli, Seite 55-64 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kaur, Harpreet [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AC133 Antigen |
|---|
| Anmerkungen: |
Date Completed 03.07.2017 Date Revised 09.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.canlet.2016.04.020 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM259622842 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM259622842 | ||
| 003 | DE-627 | ||
| 005 | 20231224191611.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.canlet.2016.04.020 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0865.xml |
| 035 | |a (DE-627)NLM259622842 | ||
| 035 | |a (NLM)27102002 | ||
| 035 | |a (PII)S0304-3835(16)30255-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kaur, Harpreet |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.07.2017 | ||
| 500 | |a Date Revised 09.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2016 Elsevier Ireland Ltd. All rights reserved. | ||
| 520 | |a Glioblastoma (GBM) contains a population of stem-like cells that promote tumor invasion and resistance to therapy. Identifying and targeting stem cell factors in GBM may lead to the development of more effective therapies. High Mobility Group AT-hook 2 (HMGA2) is a transcriptional modulator that mediates motility and self-renewal in normal and cancer stem cells. We identified increased expression of HMGA2 in the majority of primary human GBM tumors and cell lines compared to normal brain. Additionally, HMGA2 expression was increased in CD133+ GBM neurosphere cells compared to CD133- cells. Targeting HMGA2 with lentiviral short hairpin RNA (shRNA) led to decreased GBM stemness, invasion, and tumorigenicity. Ectopic expression of HMGA2 in GBM cell lines promoted stemness, invasion, and tumorigenicity. Our data suggests that targeting HMGA2 in GBM may be therapeutically beneficial | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Clonogenicity | |
| 650 | 4 | |a GSC | |
| 650 | 4 | |a Glioma | |
| 650 | 4 | |a HMGI-C | |
| 650 | 4 | |a Motility | |
| 650 | 7 | |a AC133 Antigen |2 NLM | |
| 650 | 7 | |a HMGA2 Protein |2 NLM | |
| 650 | 7 | |a PROM1 protein, human |2 NLM | |
| 700 | 1 | |a Ali, Sabeen Zulfiqar |e verfasserin |4 aut | |
| 700 | 1 | |a Huey, Lauren |e verfasserin |4 aut | |
| 700 | 1 | |a Hütt-Cabezas, Marianne |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, Isabella |e verfasserin |4 aut | |
| 700 | 1 | |a Mao, Xing-Gang |e verfasserin |4 aut | |
| 700 | 1 | |a Weingart, Melanie |e verfasserin |4 aut | |
| 700 | 1 | |a Chu, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez, Fausto J |e verfasserin |4 aut | |
| 700 | 1 | |a Eberhart, Charles G |e verfasserin |4 aut | |
| 700 | 1 | |a Raabe, Eric H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer letters |d 1976 |g 377(2016), 1 vom: 10. Juli, Seite 55-64 |w (DE-627)NLM000147273 |x 1872-7980 |7 nnns |
| 773 | 1 | 8 | |g volume:377 |g year:2016 |g number:1 |g day:10 |g month:07 |g pages:55-64 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.canlet.2016.04.020 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 377 |j 2016 |e 1 |b 10 |c 07 |h 55-64 | ||